{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:27:16Z","timestamp":1767652036454},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2,15]]},"DOI":"10.2146\/ajhp090101","type":"journal-article","created":{"date-parts":[[2010,2,4]],"date-time":"2010-02-04T14:50:45Z","timestamp":1265295045000},"page":"295-299","source":"Crossref","is-referenced-by-count":1,"title":["Drug costs and utilization after implementation of a posaconazole prophylaxis protocol in adults with acute myelogenous leukemia"],"prefix":"10.1093","volume":"67","author":[{"given":"Carrie W.","family":"Nemerovski","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Wayne State University, Detroit, MI; at the time of writing she was Cardiology Specialty Resident, University of Michigan Hospitals and Health Centers (UMHHC), Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily R.","family":"Mackler","sequence":"additional","affiliation":[{"name":"Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl D.","family":"DePestel","sequence":"additional","affiliation":[{"name":"Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis D.","family":"Collins","sequence":"additional","affiliation":[{"name":"Infectious Diseases, UMHHC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen S.","family":"Welch","sequence":"additional","affiliation":[{"name":"University of Michigan Center for Statistical Consultation and Research, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Stevenson","sequence":"additional","affiliation":[{"name":"UMHHC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041104234946500_b1-0670295","volume-title":"Noxafil (posaconazole) product information","year":"2006"},{"key":"key\n\t\t\t\t2019041104234946500_b2-0670295","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041104234946500_b3-0670295","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2002-05-1356","article-title":"Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies","volume":"101","author":"Cornely","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104234946500_b4-0670295","unstructured":"National Comprehensive Cancer Network. NCCN practice guidelines in oncology. Prevention and treatment of cancer related infections. v.1.2008. www.nccn.org (accessed 2008 Jan 16)."},{"key":"key\n\t\t\t\t2019041104234946500_b5-0670295","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041104234946500_b6-0670295","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"key":"key\n\t\t\t\t2019041104234946500_b7-0670295","volume-title":"Common toxicity criteria, version 2.0","author":"Cancer Therapy Evaluation Program","year":"1998"},{"key":"key\n\t\t\t\t2019041104234946500_b8-0670295","volume-title":"2008 Red book","year":"2008"},{"key":"key\n\t\t\t\t2019041104234946500_b9-0670295","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkm389","article-title":"Antifungal serum concentration monitoring: an update","volume":"61","author":"Goodwin","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041104234946500_b10-0670295","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.2146\/ajhp070588","article-title":"Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia","volume":"65","author":"Collins","year":"2008","journal-title":"Am J Health-Syst Pharm"},{"key":"key\n\t\t\t\t2019041104234946500_b11-0670295","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1600-0609.2008.01141.x","article-title":"Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands","volume":"81","author":"Stam","year":"2008","journal-title":"Eur J Haematol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/67\/4\/295\/28343492\/ajhp0295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T12:48:27Z","timestamp":1558788507000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/67\/4\/295\/5130034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,15]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,2,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp090101","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,2,15]]},"published":{"date-parts":[[2010,2,15]]}}}